Austar Lifesciences Ltd. (6118) AI Stock Analysis

• Market Cap: HK$420.32M
• Dividend Yield: N/A
• Average Volume (3M): 695.30K
• Price to Earnings (P/E): 12.2
• Beta (1Y): 0.75
• Revenue Growth: -2.77%
• EPS Growth: N/A
• Country: HK
• Employees: 1,445
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.02
• Shares Outstanding: 512,582,030
• 10 Day Avg. Volume: 1,360,300
• 30 Day Avg. Volume: 695,300
• PEG Ratio: -0.15
• Price to Book (P/B): 0.35
• Price to Sales (P/S): 0.18
• P/FCF Ratio: 3.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: HK$0.85 ▼(-4.72% Downside)
• Action: Reiterated Date: 11/12/25
• Date: Action: Reiterated 11/12/25

Austar Lifesciences Ltd. receives an overall score of 52, driven primarily by its mixed financial performance and reasonable valuation. The stock's technical indicators suggest weak momentum, which impacts its attractiveness. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Positive free cash flow and cash conversion

Free cash flow turned positive in 2024 and operating cash conversion is strong. Persistently positive FCF improves the company’s ability to fund R&D, support commercialization and licensing initiatives, and reduce reliance on external financing, strengthening resilience over months.

Negative Factors

Inconsistent revenue growth

Negative recent revenue growth and a choppy top-line trend undermine predictability for a development-stage biotech. Weak or inconsistent sales complicate R&D budgeting, licensing negotiations and long-term planning, making sustained margin recovery and scale harder to achieve.

Austar Lifesciences Ltd. Business Overview & Revenue Model

Company Description

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Biopr...

Read more

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Biopr...

How the Company Makes Money

Austar Lifesciences Ltd. generates revenue through multiple streams, primarily from the sale of its developed pharmaceutical products and licensing agreements with other biotech firms and pharmaceutical companies. The company invests significantly...

Read more

Austar Lifesciences Ltd. generates revenue through multiple streams, primarily from the sale of its developed pharmaceutical products and licensing agreements with other biotech firms and pharmaceutical companies. The company invests significantly...

Austar Lifesciences Ltd. Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.46B	1.50B	1.76B	2.16B	2.02B	1.30B
Gross Profit	294.94M	301.22M	336.05M	488.80M	479.01M	323.53M
EBITDA	72.28M	70.71M	25.15M	159.79M	130.62M	39.83M
Net Income	35.20M	16.08M	-113.47M	87.46M	277.30M	33.10M
Balance Sheet
Total Assets	2.03B	2.08B	2.16B	2.39B	2.04B	1.38B
Cash, Cash Equivalents and Short-Term Investments	165.66M	167.81M	173.76M	148.13M	219.74M	178.11M
Total Debt	357.16M	401.95M	496.20M	336.55M	155.22M	76.47M
Total Liabilities	1.22B	1.29B	1.38B	1.51B	1.26B	854.27M
Stockholders Equity	809.35M	791.41M	773.01M	896.94M	786.58M	517.90M
Cash Flow
Free Cash Flow	112.53M	78.31M	-133.59M	-155.25M	-204.02M	25.68M
Operating Cash Flow	118.23M	98.81M	-62.65M	-37.93M	-103.45M	52.22M
Investing Cash Flow	-10.68M	4.43M	-54.47M	-153.14M	65.02M	-59.81M
Financing Cash Flow	-83.52M	-101.32M	147.12M	125.30M	59.35M	-5.51M

Austar Lifesciences Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.89
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6118, the sentiment is Neutral. The current price of 0.89 is above the 20-day moving average (MA) of 0.75, above the 50-day MA of 0.80, and below the 200-day MA of 1.00, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 47.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6118.

Austar Lifesciences Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1612	71 Outperform	HK$619.83M	5.13	16.21%	4.94%	17.93%	36.82%
2500	53 Neutral	HK$961.41M	-1.91	-30.05%	―	-8.56%	-14.84%
6118	52 Neutral	HK$420.32M	12.16	4.12%	―	-2.77%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2170	44 Neutral	HK$574.40M	-2.91	-16.83%	―	11.43%	4.88%
2216	41 Neutral	HK$724.37M	-4.03	-9.19%	―	-30.60%	28.61%
2393	40 Underperform	HK$221.32M	10.43	-34.76%	―	6.10%	-115.12%